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Abstract: Although non-alcoholic fatty liver disease (NAFLD), characterised by the accumulation
of triacylglycerol in the liver, is the most common liver disorder, the causes of its development
and progression to the more serious non-alcoholic steatohepatitis (NASH) remain incompletely
understood. Oxidative stress has been implicated as a key factor in both these processes, and
mitochondrial dysfunction and inflammation are also believed to play a part. Coenzyme Q (CoQ)
is a powerful antioxidant found in all cell membranes which has an essential role in mitochondrial
respiration and also has anti-inflammatory properties. NAFLD has been shown to be associated with
disturbances in plasma and liver CoQ concentrations, but the relationship between these changes
and disease development and progression is not yet clear. Dietary supplementation with CoQ
has been found to be hepatoprotective and to reduce oxidative stress and inflammation as well
as improving mitochondrial dysfunction, suggesting that it may be beneficial in NAFLD. However,
studies using animal models or patients with NAFLD have given inconclusive results. Overall,
evidence is now emerging to indicate that disturbances in CoQ metabolism are involved in NAFLD
development and progression to NASH, and this highlights the need for further studies with human
subjects to fully clarify its role.
Keywords: non-alcoholic fatty liver disease; non-alcoholic steatohepatitis; Coenzyme Q;
antioxidant; oxidative stress; inflammation; steatosis
1. Introduction
Non-alcoholic fatty liver disease (NAFLD), a condition in which triacylglycerol (TAG)
accumulates in the liver, is the most common liver disorder worldwide [1,2]. Its occurrence in
the general population has been estimated to be 20%–30%, but in increasingly prevalent metabolic
disorders, including obesity, diabetes type 2 and the metabolic syndrome, this rises to 70%–90%.
NAFLD itself is considered to be relatively benign, but in some cases its progression leads to liver
conditions such as non-alcoholic steatohepatitis (NASH), fibrosis, cirrhosis and carcinoma which
are more serious and may be life-threatening [1,2]. A better understanding of the causes of the
development and progression of the disease, therefore, is now of great importance from a public
health perspective [1,2].
NAFLD is known to be a multifactorial disease, but the reasons why progression occurs in
some cases but not others are not yet well defined [3,4]. Recent work, however, has indicated that
oxidative stress resulting from both insulin resistance and hepatic steatosis is likely to be a major
causal factor in the development of NAFLD, and may also play an important part in its progression
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to more serious conditions such as NASH [4–7]. Coenzyme Q (CoQ) (also called ubiquinone) is an
important cellular antioxidant found in all membranes [8–10]. Supplementation of the diet with CoQ
has been found to influence plasma antioxidant and inflammatory markers in healthy men [11] and
in patients with coronary artery disease [12,13], and animal studies have demonstrated effects on
liver oxidative stress and lipid metabolism [14–16]. Furthermore, there is clear evidence to indicate
that NAFLD is associated with perturbation of plasma and hepatic CoQ levels [17–19], and recent
studies have demonstrated that CoQ metabolism is altered in an animal model of the disease [20].
Thus, there is growing evidence to suggest that disturbances in CoQ metabolism may play a part in
the development and progression of NAFLD.
2. CoQ Function and Metabolism
CoQ is a lipophilic molecule consisting of a benzoquinone ring and a polyisoprenoid side chain
(Figure 1). The side chain varies in length from species to species, and for the purposes of this review
it is important to note that in humans it contains 10 isoprene units (CoQ10), while in rats and mice,
the most commonly used animal models for NAFLD, it has 9 (CoQ9) [21]. It is found in all cell
membranes and is unique among naturally occurring lipophilic antioxidant in that it is synthesised
de novo in animals [8–10]. The best known function of CoQ is in mitochondrial respiration. The
side chain serves to keep the molecule anchored in the inner mitochondrial membrane, and the
quinone ring, which is easily and reversibly reduced to the quinol form (Figure 1), enables it to carry
out its function of transferring electrons from complexes I and II to complex III in the respiratory
chain, ultimately resulting in the reduction of oxygen to water and the generation of ATP [10,21]. In
addition to this essential role in energy generation, CoQ is now thought to have a number of other
functions in the body, including regulation of mitochondrial functions such as membrane transition
pore permeability and the activation of uncoupling proteins, counteraction of endothelial dysfunction
by stimulating nitric oxide production, and, of particular interest in relation to NAFLD, acting as
an anti-inflammatory agent and a lipophilic antioxidant protecting lipids, protein and DNA from
oxidation [8,22,23].
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Figure 1. The oxidised and reduced forms of Coenzyme Q (CoQ). The oxidised and reduced forms of 
CoQ are interconverted by the addition or loss of 2H + 2e−. n = 10 in humans and 9 in rats and mice. 
CoQ is synthesised by a complex pathway involving the conjugation of the polyprenyl side chain 
with para hydroxybenzoic acid  (PABA)  the precursor of  the benzoquinone moiety,  followed by a 
series of modifications to the ring which result in the final structure [21–23]. At least nine enzymes 
are  believed  to  participate  in  the  pathway,  and  the  steps  specific  to  CoQ  take  place  inside 
mitochondria. Isoprene monomers are synthesised via the mevalonate pathway in the cytosol, and 
are then condensed by the complex Pdss1/Pdss2, thus this enzyme determines the number of isoprene 
units  in the CoQ side chain [21–23]. Deficiency of CoQ  is known to occur  in humans and leads to 
various  mitochondrial  disorders  which  have  diverse  clinical  manifestations,  including 
encephalomyopathy, ataxia, myopathy and a nephrotic syndrome [21,24,25]. The disorders may be 
primary or secondary. Primary disorders caused by defects in the biosynthetic pathway are rare, but 
mutations in a number of the genes in the pathway, including Pdss1 and Pdss2, have been identified 
(see  reference  [21]  for  a  comprehensive  list).  Secondary  deficiencies may  result  from  defects  in 
proteins unrelated to CoQ biosynthesis such as aprataxin, which has a role in double stranded DNA 
repair, mitochondrial DNA depletion, or the use of statins to combat hypercholesterolemia [21,24,25]. 
Although  endogenous  synthesis  is  normally  able  to  meet  the  body’s  need  for  CoQ,  there  are 
Figure 1. The oxidised and reduced forms of Coenzyme Q (CoQ). The oxidised and reduced forms of
CoQ are interconverted by the addition or loss of 2H + 2e´. n = 10 in humans and 9 in rats and mice.
CoQ is synthesised by a complex pathway involving the conjugation of the polyprenyl side chain
with para hydroxybenzoic acid (PABA) the precursor of the benzoquinone moiety, followed by a
series of modifications to the ring which result in the final structure [21–23]. At least nine enzymes are
believed to participate in the pathway, and the steps specific to CoQ take place inside mitochondria.
Isoprene monomers are synthesised via the mevalonate pathway in the cytosol, and are then
condensed by the complex Pdss1/Pdss2, thus this enzyme determines the number of isoprene units
in the CoQ side chain [21–23]. Deficiency of CoQ is known to occur in humans and leads to various
mitochondrial disorders which have diverse clinical manifestations, including encephalomyopathy,
ataxia, myopathy and a nephrotic syndrome [21,24,25]. The disorders may be primary or secondary.
Primary disorders caused by defects in the biosynthetic pathway are rare, but mutations in a number
of the genes in the pathway, including Pdss1 and Pdss2, have been identified (see reference [21] for
a comprehensive list). Secondary deficiencies may result from defects in proteins unrelated to CoQ
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biosynthesis such as aprataxin, which has a role in double stranded DNA repair, mitochondrial DNA
depletion, or the use of statins to combat hypercholesterolemia [21,24,25]. Although endogenous
synthesis is normally able to meet the body’s need for CoQ, there are circumstances in which
deficiencies not caused by genetic defects may occur. Statins, drugs widely used to lower blood
cholesterol, can depress CoQ synthesis as they inhibit 3-hydroxy-3-methylglutaryl Coenzyme A
reductase (HMG-CoA reductase), the rate-limiting enzyme in the pathway of cholesterol synthesis
which includes the formation of the isoprenoid units required to produce CoQ [21,26]. In addition,
CoQ levels may be pathologically changed in conditions associated with oxidative stress and in
aging [27]. Current evidence suggest that dietary CoQ supplementation may be beneficial in many of
these cases, but it is not yet used routinely in clinical practice [24,28].
Antioxidant and Anti-Inflammatory Functions of CoQ
CoQ is biosynthesised in all tissues of the body, and, although it was initially believed to be
confined to the inner mitochondrial membrane because of its function in the respiratory chain [29],
it is now know to be present in all cell membranes [8,23]. Because of its widespread distribution
and membrane location, CoQ is the most highly efficient of the naturally occurring lipophilic
antioxidants [8]. In the membrane CoQ is in close proximity to lipid and protein molecules in need
of protection from locally produced peroxy radicals. Much of the CoQ found in the body is in the
antioxidant quinol form (Figure 1), although this varies between tissues [8]. The quinol prevents
lipid peroxidation by inhibiting the initial formation and propagation of lipid peroxy radicals (LOO),
and in the process it is oxidised to the quinone (Figure 1) and H2O2 is produced. In addition, it has
been shown to protect proteins from oxidation by a similar mechanism [30], and to prevent oxidative
DNA damage such as strand breakages [8,31]. As well as its role in membranes, CoQ is also believed
to function in the blood to protect lipoproteins such as very low density (VLDL), low density (LDL)
and high density (HDL) lipoproteins from oxidation [8]. The oxidised quinone product is rapidly
and efficiently reduced to the quinol by enzyme systems in both the blood and the tissues, thus
maintaining a high level of the active form [8].
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Figure  2.  Antioxidant  and  anti‐inflammatory  functions  of  CoQ.  Lipids,  proteins  and DNA  and 
lipoproteins in the blood are protected from oxidative damage by the conversion of the quinone form 
of CoQ to the quinol form. The quinol is rapidly reconverted to the quinone in both blood and tissues. 
CoQ has also been shown to decrease cytokine secretion in monocytes and lymphocytes, to improve 
endothelial function and to reduce hepatic inflammatory stress. 
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protein oxidation and the production of pro‐inflammatory cytokines [5,49]. Recent studies have also 
suggested that oxidative stress may be a primary cause of liver fat accumulation [50], and ROS have 
also  been  shown  to  play  a  part  in  fibrosis  development  [51].  In  addition,  blood  antioxidant 
concentrations have been  reported  to be decreased  in patients with NAFLD  [52].  It  is now  clear, 
therefore, that oxidative stress is a major factor in the development of NAFLD and its progression to 
NASH.  Furthermore,  a  large  proportion  of  cellular  ROS  are  produced  in  mitochondria,  and 
overproduction  of  ROS when mitochondrial  respiration  is  disrupted  has  been  suggested  to  be 
important in NAFLD development [53–55]. The presence of mitochondrial dysfunction in patients 
Figure 2. Antioxidant and anti-inflammatory functions of CoQ. Lipids, proteins and DNA and
lipoproteins in the blood are protected from oxidative damage by the conversi n of the quinone form
of CoQ to the quinol form. The quinol is rapidly reconverted to the quinone in both blood and tissues.
CoQ has also been shown to decrease cytokine secretion in monocytes and lymphocytes, to improve
endothelial function and to reduce hepatic inflammatory stress.
As well s ac ing as an efficient antioxidant, current evidence suggests that CoQ has a number
of independent anti-inflammatory effects [31,32]. It has been shown to reduce the secretion of
pro-inflammatory cytokines in monocytes and lymphocytes after an inflammatory stimulus via
an influence on the expression of NF-κB-dependent genes [14,24,33,34]. Furthermore, dietary
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supplementation with CoQ10 has been reported to improve endothelial dysfunction in patients
with diabetes by up-regulating nitric oxide production (patients received 200 mg CoQ10/day for
12 weeks) [24,35,36], and to decrease the hepatic inflammatory stress caused by obesity in mice
(see below) [14].
CoQ therapy has an obvious application in mitochondrial disease [28,37], but its antioxidant
and anti-inflammatory effects have led to considerable interest in its possible beneficial effects in
other chronic diseases, in particular cardiovascular disease [38,39], but also in neurodegenerative
disorders including Parkinson’s disease, Huntington’s disease and Freidreich’s ataxia [38,40–42]. It
has also been reported to reduce the risk of pre-eclampsia in pregnancy and to increase sperm quality
in infertile men [38,43,44]. The list of conditions influenced by CoQ continues to grow, and below
we present evidence from recent studies that suggests that changes in its metabolism may also have
a role in NAFLD development and progression. The antioxidant and anti-inflammatory functions of
CoQ are summarised in Figure 2.
3. Pathogenesis of NAFLD Development and Progression
NAFLD is defined as the presence of abnormal fat deposition in the liver (steatosis) without
inflammation in individuals who do not consume excessive amounts of alcohol, and its occurrence
is strongly associated with metabolic disorders such as obesity, diabetes and the metabolic
syndrome [1,2]. The simple steatosis may progress to non-alcoholic steatohepatitis (NASH) (about
25% of cases), in which the fat accumulation is accompanied by inflammation and hepatocyte
ballooning. Approximately 20% of NASH patients will develop fibrosis and cirrhosis, and in 1%
of cases per year cirrhosis progresses to liver carcinoma [2]. The hepatic diseases and main clinical
conditions involved in NAFLD development are well known and described in terms diagnostic
criteria [45], and, although the pathogenesis from healthy liver to the disease condition remains
incompletely understood, oxidative stress and insulin resistance have been strongly implicated as
causative factors [5,46].
The finding that the risk of progression of NAFLD to NASH is related to the severity of fat
deposition led Day et al. [47] to propose the “two hit” hypothesis in 1998. The first hit is the
simple hepatic steatosis which results from the development of insulin resistance, and this leads
to conditions in which the liver becomes more sensitive to the second hits which include oxidative
stress, mitochondrial dysfunction and inflammation [2,4,47]. More recently, however, it has become
clear that polymorphism in the gene for patatin-like phospholipase 3 (PNPLA3) also plays a role in
NASH development, thus it is more accurately described as a multiple hit process [4].
In the normal liver, there is a balance between the synthesis and esterification of fatty acids
(FFA) which increases hepatic TAG content, and VLDL secretion and fatty acid oxidation which
decreases it [48]. In insulin resistance, however, there is an increased supply of fatty acids to
hepatocytes, causing not only fat accumulation but also a rise in mitochondrial β-oxidation, and
consequently increased oxidative stress caused by raised levels of reactive oxygen species (ROS),
lipid peroxidation, protein oxidation and the production of pro-inflammatory cytokines [5,49]. Recent
studies have also suggested that oxidative stress may be a primary cause of liver fat accumulation [50],
and ROS have also been shown to play a part in fibrosis development [51]. In addition, blood
antioxidant concentrations have been reported to be decreased in patients with NAFLD [52]. It is
now clear, therefore, that oxidative stress is a major factor in the development of NAFLD and its
progression to NASH. Furthermore, a large proportion of cellular ROS are produced in mitochondria,
and overproduction of ROS when mitochondrial respiration is disrupted has been suggested to
be important in NAFLD development [53–55]. The presence of mitochondrial dysfunction in
patients with NASH also indicates that it is likely to have important role in the pathogenesis of
the disease [56,57]. Figure 3 summarises current ideas on the pathogenesis of NAFLD development
and progression.
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Figure  3.  The  development  and  progression  of NAFLD.  The  development  of  insulin  resistance 
increases the supply of free fatty acids (FFA) to the liver causing increased TAG synthesis and hepatic 
steatosis. Oxidative stress may also contribute to this process. The steatosis leads to inflammation and 
increased  oxidative  stress,  which  in  turn  causes  mitochondrial  dysfunction.  These  conditions, 
together with other factors such as PNPLA3 gene polymorphism, result in the development of fibrosis 
and ultimately NASH. In the traditional 2 hit hypothesis [48] the initial steatosis is the first hit and the 
second hits are the resulting oxidative stress and inflammation. It is now clear, however, that multiple 
hits are involved in the process. 
4. CoQ and NAFLD Development and Progression 
Both the role of CoQ in mitochondria and its function as an efficient endogenously synthesised 
antioxidant [8,10,21] suggest that it may play a part in the development of NAFLD and its progression 
to NASH, and evidence for this has begun to emerge from recent investigations. In general, two main 
approaches have been used. The first has been to study the relationship between the disease and CoQ 
metabolism in the body and the second to assess the influence of dietary supplementation with CoQ 
on  the development of  the condition. So  far,  the majority of studies have used animal models of 
NAFLD or NASH, mainly  in rats and mice, but as  interest grows, more human studies are being 
undertaken. 
Studies to date on how CoQ metabolism is changed in NAFLD have given conflicting results. 
As early as 1996, Eaton et al. [18] suggested from their work on β‐oxidation in patients with alcoholic 
and non‐alcoholic liver disease that decreased amounts of CoQ may contribute to hepatic steatosis in 
NASH  , and more recently, Yesilova et al. [19] found that CoQ10 levels were depleted in men with 
NAFLD in comparison with normal subjects. Moreover, these authors also showed that there was a 
negative correlation between CoQ10 and body fat and also inflammatory activity and fibrosis [19]. In 
an investigation with obese rats, exposure of the animals to a mixture of environmental contaminants 
implicated in NAFLD development and progression has been reported to cause a decrease in liver 
CoQ10 concentrations [57], and the activity of geranylgeranyl pyrophosphate synthase, an enzyme 
involved  in  the  formation of  isoprene units, was also decreased  in  these  conditions. The authors 
conclude from this that de novo synthesis of CoQ is depressed in NAFLD, but measurement of levels 
Figure 3. The development and progression of NAFLD. The developm nt of insulin resistance
increases the supply of free fatty acids (FFA) to the liver causing increased TAG synthesis and hepatic
steatosis. Oxidative stress may also contribute to this process. The steatosis leads to inflammation
and increased oxidative stress, which in turn cause mitochondrial dysfunction. These conditions,
together with other factors such as PNPLA3 gene poly orphism, result in the development of fibrosis
and ultimately NASH. In the traditional 2 hit hypothesis [48] the initial steatosis is the first hit and the
second hits are the resulting oxidative stress and inflammation. It is now clear, however, that multiple
hits are involved in the process.
4. CoQ and NAFLD Development and Progression
Both the role of CoQ in mitochondria and its function as an efficient endogenously synthesised
antioxidant [8,10,21] suggest that it may play a part in th developm nt of NAFLD and its progression
to NASH, and evidence for this has begun to emerge from recent investigations. In general, two
main approaches have been used. The first has been to study the relationship between the disease and CoQ
metabolism in the body and th second to asses the influence of dietary s pplementation with CoQ on the
development of the condition. So far, the majority of studies have used animal models of NAFLD or
NASH, mainly in rats and mice, but as interest grows, more human studies are being undertaken.
Studies to date on how CoQ metabolism is changed in NAFLD have given conflicting results.
As early as 1996, Eaton et al. [18] suggested from their work on β-oxidation in patients with alcoholic
and non-alcoholic liver disease that decr ased amounts of CoQ may contribute to epatic steatosis
in NASH , and more recently, Yesilova et al. [19] found that CoQ10 levels were depleted in men with
NAFLD in comparison with normal subjects. Moreover, these authors also showed that there was a
negative correlation between CoQ10 and body fat and also inflammatory activity and fibrosis [19]. In
an investigation with obese rats, exposure of the animals to a mixture of environmental contaminants
implicated in NAFLD development and progression has been reported to cause a decrease in liver
CoQ10 concentrations [57], and the activity of geranylgeranyl pyrophosphate synthase, an enzyme
involved in the formation of isoprene units, was also decreased in these conditions. The authors
conclude from this that de novo synthesis of CoQ is depressed in NAFLD, but measurement of
levels of CoQ9, the main endogenous form in rats, would be required to confirm this. In contrast,
Bravo et al. [20] found that plasma levels of CoQ9 were increased in rats with high fat diet-induced
NAFLD, while concentrations of CoQ10, which is likely to be mainly derived from exogenous sources, were
not significantly changed. Furthermore, there was an increase of about 75% in the proportion of
total plasma CoQ (CoQ9 + CoQ10) in the reduced form. Another study using a mouse model of
NASH found increased levels of plasma CoQ9 in the animals, and the rise was positively correlated
with hepatic ROS concentrations, hypercholesterolemia and fibrosis [58]. Since increases were
observed in CoQ9, but not CoQ10 in these experiments [20,58], it seems likely that this change reflects
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up-regulation of endogenous synthesis which may be an protective response against a general
reduction in the antioxidant capacity of the plasma which occurs in NAFLD [15,52]. In addition,
respiratory activity and the activity of liver mitochondrial NADH-CoQ oxidoreductase (complex I
of the respiratory chain) have been shown to be decreased in rats with NAFLD induced by choline
deficiency [9]. Current evidence, therefore, clearly indicates that CoQ metabolism is disturbed in
NAFLD, but further studies are required to elucidate how exactly this relates to the development
and progression of the disease.
The finding that changes in CoQ metabolism are potentially involved in the development and
progression of NAFLD raises the question of whether dietary supplementation with the quinone
may be beneficial in the prevention or treatment of the condition. Although only a few studies
have investigated the direct effects of CoQ supplementation on NAFLD (see below), a number
of investigations in both humans and animals have provided evidence in areas known to be
associated with the disease such as oxidative stress and mitochondrial dysfunction (studies on dietary
supplementation with CoQ are summarised in Table 1). Despite the fact that CoQ9 is the endogenous
form in rats and mice, with just a few exceptions (see below), investigations with animals have used
CoQ10 as the dietary supplement.
Dietary supplementation with CoQ10 (300 mg/day for 12 days) has been found to reduce
serum markers of oxidative stress in young swimmers [59] and, in a series of studies in patients
with coronary artery disease (60–300 mg CoQ 10/day for 12 weeks) , to reduce oxidative stress
and increase the activity of antioxidant enzymes as well as lowering inflammation as assessed by
plasma levels of inflammatory markers such as tumour necrosis factor (TNF)-α and interleukin
(IL)-6 [12,13,60,61]. Similarly, dietary CoQ (diet supplemented with 0.07%–0.7% (w/w) CoQ10 for
26 weeks) was associated with a reduction in plasma oxidative stress and inflammatory markers in a
rat model of the metabolic syndrome [62]. In healthy sedentary men given oral CoQ10 (100 mg/day
for 8 weeks), however, Gobkel et al. [11] reported that blood levels of TNF-α and interleukin (IL)-6
were unchanged over the 8 week experimental period.
In the liver in general, animal studies have shown that dietary CoQ10 is hepatoprotective against
toxic agents including acetaminophen (rats were given a single oral dose of acetaminophen (700 mg/kg),
two injections (i.p.) of CoQ10 at 1 and 12 h and killed at 24 h) and carbon tetrachloride (a single
i.p. dose of 200 mg/kg CoQ10 was administered 24 h before injection of CCl4 (1 mL/kg) s.c. and
animals were killed 24 h later) in rats [63,64], inhibits liver fibrosis induced by dimethylnitrosamine
(DMN) (10 or 30 mg CoQ10 given orally before administration of mDMN and 3 times/week
thereafter for 3 weeks) or eggs of the parasitic worm Schistoma mansoni (S. mansoni) (oral dose of
5 mg/kg CoQ10 daily for 8 or 12 weeks after infection) in mice [65,66], and limits ischemic damage in
transplanted livers when the donor rat is pretreated (10 mg/kg CoQ10 given i.v. 1 h before induction
of ischemia) [67]. Intraperitoneal administration of CoQ10 (8 mg i.p. every second day for 38 days)
has been shown to lower liver TAG content in rats [68], suggesting that it could be protective against
hepatic fat deposition in NAFLD. Hepatic oxidative stress and inflammation has also been found
to be reduced by CoQ10 therapy in several animal studies. In a model of diet-induced obesity, a
high risk condition for NAFLD development in mice, Sohet et al. [14] showed that the expression
of mRNA for a panel of hepatic genes involved in ROS production, inflammation and metabolic stress
was reduced in the animals fed CoQ (diet supplemented with 1% CoQ10 for 60 days), and Othman et al. [66],
also found that the quinone decreased oxidative stress and preserved antioxidant factors in livers
of mice infected with S. mansoni (study details given above). In contrast, in another study although
both CoQ9 and CoQ10 levels in the liver were increased in rats fed a diet supplemented with CoQ10
(62 mg/kg) for 6 or 12 months, the activities of the hepatic antioxidant enzymes measured were either
unchanged or decreased [69]. Hepatic mitochondrial dysfunction has also been shown to be improved by
CoQ10 (0.57 mg/day for 6 weeks) in rats given a high cholesterol diet and atorvastatin [70] and in
cultured human hepatocytes treated with D-galactosamine, an inducer of oxidative stress and cell
death and 30 µM CoQ [71].
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Table 1. Summary of studies on the effects of dietary CoQ supplementation on NAFLD and related factors.
Subjects/Animals/Cells Oxidative Stress (OS) Inflammation Other References
Young swimmers
Plasma OS markers MDA, NO,
protein hydroperoxide decreased;
total antioxidant capacity increased
[59]
Patients with coronary artery
disease
Plasma MDA reduced; SOD, CAT,
GPx activites increased Plasma TNF-α, IL-6 reduced [12,13,60,61]
Rats with the metabolic syndrome Plasma oxidised LDL decreased Plasma hsCRP reduced Endothelial dysfunction improved [62]
Healthy sedentary men Plasma TNF-α, IL-6 levelsunchanged [11]
Rats with liver injury induced by
acetominophen or CCl4
Liver GSH increased; lipid
peroxides decreased
Liver tissue damage ameliorated;
liver NF-κB, caspase 3 and
inducible NO synthase
[63,64]
Mice with diet-induced obesity Liver expression of NADPHoxidase decreased
Liver expression of CRP, STAMP2
decreased
Liver expression of CPT1α
decreased [14]
Mice with liver fibrosis induced by
DMN or S mansoni
Liver MDA decreased; GSH
increased
Liver TGF-β reduced, Nrf2/ARE
activated Liver fibrosis decreased [65,66]
Liver transplantation donor rats Ischemic damage in transplantedliver prevented [67]
Rats (CoQ10 given IP) Lipid content of liver decreased [68]
Rats fed sunflower oil or olive oil Liver antioxidant enzyme activitiesunchanged or decreased [69]
Rats fed a high cholesterol diet and
atorvastatin
Serum and liver cholesterol and TG
lowered; mitochondrial respiration
improved
[70]
Rats with diet-induced NAFLD * Plasma oxidised CoQ9 increased
Liver injury, steatosis, VLDL
production unchanged; microsomal
apoB, TG and membrane
phospholipid increased; plasma
leptin increased
[15,16]
Cultured human hepatocytes
treated with D-galactosamine ROS generation decreased
Electron transport chain
dysfunction improved [71]
Humans with NAFLD Serum total antioxidant capacitydecreased
Serum AST decreased, waist
circumference decreased [46]
Humans with NAFLD Oxidative stress staus unchanged No beneficial effects on serum lipidprofile or blood pressure [72]
ARE: antioxidant response element; AST: aspartate aminotransferase; CAT: catalase; CPT1α: carnitine palmitoyl transferase 1α; CRP: C-reactive protein; DMN: dimethylnitrosamine;
GPx: glutathione peroxidase; GSH: reduced glutathione; hsCRP: high sensitivity CRP; MDA: malondialdehyde; SOD: superoxide dismutase; STAMP2: six transmembrane protein
of prostate 2. *CoQ9 was used as the dieatry supplement. In all other studies listed CoQ10 was used.
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The studies discussed above suggest that CoQ therapy may be beneficial effect in alleviating
some of the causal factors of NAFLD, including oxidative stress, inflammation and mitochondrial
dysfunction. Building on this base, our group investigated the direct effects of dietary
supplementation with CoQ9 on the development of the disease using a high fat diet- induced model
in rats [15,16]. CoQ9 was used rather that CoQ10 as it is the main endogenously synthesised form in
the test species [21]. We used a dose of 30 mg/kg/day CoQ9 for 8 weeks after feeding a high fat diet
for 10 weeks. NAFLD was found to be associated with increased, rather than reduced, plasma CoQ9
levels, while CoQ10 (mostly originating from the diet) concentrations were unaffected. However,
the ratio of CoQ9:CoQ10 was significantly higher in NAFLD rats given the dietary supplement and
plasma oxidized CoQ9 levels were also raised, effects which may be responses to increased oxidative
stress [15]. Dietary CoQ9 was not found to have significant effects on hepatic steatosis, liver injury, the
development of insulin resistance or increased production of VLDL seen in NAFLD, although it did
cause a rise in plasma leptin levels, an effect which is likely to be detrimental rather than beneficial.
Under normal physiological conditions, the liver produces and secretes VLDL when energy for
peripheral tissues is needed. TAG is transferred into the endoplasmic reticulum (ER), where it enters
the VLDL precursor pathway [73]. In NAFLD, however, there is overproduction of large, TAG-rich
VLDL causing hypertriglyceridemia [74]. Since a number of crucial steps in VLDL synthesis depend
on the proper functioning of the ER membrane [73], Cano and colleagues carried out another study
to investigate the effects of dietary CoQ9 on hepatic VLDL processing in rats with NAFLD [16]. CoQ9
was shown to have a number of effects including increasing microsomal levels of apoB and TAG and
changing the microsomal membrane phospholipid content [16]. This kind of membrane change could
delay the transfer of the nascent lipoproteins out of the ER into the secretory pathway, triggering
increased apoB synthesis and TAG-rich VLDL particle size, and leading to the secretion of larger
particles while the total concentration of VLDL TAG remains unchanged. Thus, although dietary
CoQ9 was shown to affect VLDL secretion in hepatic steatosis, the changes may not be beneficial as
they could lead to the production of larger, more atherogenic VLDL.
In human subjects with NAFLD, oral CoQ10 (100 mg/day for 4 weeks) has been reported to
reduce waist circumference and decrease serum levels of aspartate aminotransferase, but was also
found to decrease serum total antioxidant capacity [46], and in a second study (100 mg daily for
12 weeks), no beneficial effects were found [72]. Clearly, in considering dietary supplementation
with CoQ as a therapy for NAFLD, it is important to establish whether it is able to bring about a
reduction in hepatic fat accumulation and to prevent the development of fibrosis and carcinoma in
the longer term. Because of the limited number of studies which have investigated effects on NAFLD
directly, however, conclusive evidence is not yet available in these areas. CoQ administration has been
reported to decrease hepatic steatosis in rats in one study [68], but in our work using a rat model of
NAFLD we found no change [15]; liver fibrosis and hepatocellular carcinoma have been shown to be
inhibited in rodents [65,66,75], but in these cases the conditions were induced chemically rather than
as a result of NAFLD/NASH. Overall, therefore, studies to date, have not shown any direct benefit
of CoQ therapy in combatting NAFLD development, however, as they are so few there is clearly a
need for further investigations, and in particular for more human intervention studies, before any
definitive conclusions can be reached.
5. Summary and Conclusions
Recent research has shown that oxidative stress, mitochondrial dysfunction and inflammation
are key factors in the development of NAFLD and its progression to NASH [2,4,47]. The essential
role of CoQ in mitochondria, therefore, together with its function as an efficient, endogenously
synthesised antioxidant and its anti-inflammatory properties [8,10,21,24] suggest that disturbances
in its metabolism may be involved in the pathogenesis of the disease, and evidence for this is now
emerging. Investigations, mainly using animal models so far, have shown that CoQ metabolism
is altered as NAFLD progresses, although its exact relationship to the disease process remains
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to be determined. Experiments with both animals and humans have demonstrated that dietary
supplementation with CoQ is potentially beneficial for NAFLD, since it reduces oxidative stress and
inflammation, improves mitochondrial dysfunction and is generally hepatoprotective. However, only
a few studies either in animal models or in patients have assessed the direct effects of dietary CoQ
in NAFLD to date, and the results have been inconclusive. Despite this, current evidence clearly
indicates that CoQ is likely to be involved in NAFLD development and further studies, particularly
with human subjects, are needed both to fully elucidate its role and to resolve the question of the
efficacy of CoQ therapy in alleviating the effects of the condition.
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